BTIG Reiterates Buy on Zevra Therapeutics, Raises Price Target to $27
Benzinga Newsdesk 4 months ago
NewsPrice TargetReiterationAnalyst Ratings
BTIG analyst Kambiz Yazdi reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $27.
BTIG analyst Kambiz Yazdi reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $27.